-
AVOIDABLE DIRECT COSTS IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) TREATED WITH DAROLUTAMIDE: A REAL-WORLD EVIDENCE FROM A MULTICENTER STUDY IN COLOMBIA
Mar 18, 2026, 21:38 PM -
COPD IN THE UNITED STATES: FACTORS AFFECTING TREATMENT PATTERNS AND UTILIZATION OF PHARMACOTHERAPY
Mar 18, 2026, 21:38 PM -
METHODOLOGICAL INSIGHTS INTO VACCINE HESITANCY RESEARCH IN RESPIRATORY DISEASES IN ADULTS AT-RISK: SYSTEMATIC REVIEW
Mar 18, 2026, 21:38 PM -
FUTURE-PROOFING UK HTA: CAN NICE ABSORB MFN-INDUCED PRICE INCREASES?
Mar 18, 2026, 21:38 PM -
PATIENT PREFERENCES AND WILLINGNESS TO USE TELEMEDICINE COMPARED WITH IN-PERSON CARE IN PAKISTAN
Mar 18, 2026, 21:38 PM -
THE ROLE OF INNOVATIVE CONTRACTS IN ADDRESSING UNMET MEDICAL NEEDS FOR HIGH-BUDGET-IMPACT THERAPIES: EVIDENCE FROM THERAPEUTIC ANALOGUES AND IMPLICATIONS FOR OBESITY
Mar 18, 2026, 21:38 PM -
AN AUTOMATED NETWORK META-ANALYSIS FRAMEWORK INTEGRATING INTELLIGENT ALGORITHMS AND LARGE LANGUAGE MODELS
Mar 18, 2026, 21:38 PM -
DEVELOPMENT OF AN INDIVIDUAL-LEVEL SIMULATION MODEL TO ASSESS THE COST CONSEQUENCES OF CARDIOVASCULAR-RENAL-METABOLIC SCREENING POLICIES FROM A NATIONAL PAYER AND SOCIETAL PERSPECTIVE
Mar 18, 2026, 21:38 PM -
A METHOD FOR CALCULATING THE TOTAL QALY OUTPUT AND THE MEAN COST/QALY ATTRIBUTABLE TO THE HEALTH SECTOR; THE CASE OF THE UK
Mar 18, 2026, 21:38 PM -
AUTOMATED AMCP DOSSIER DEVELOPMENT USING A RETRIEVAL-AUGMENTED GENERATION (RAG)-BASED MULTI-AGENT APPROACH
Mar 18, 2026, 21:38 PM -
CAREGIVER BURDEN AND SOCIOECONOMIC IMPACT OF HE AND OHE AMONG INDIVIDUALS CARING FOR PATIENTS WITH CIRRHOSIS
Mar 18, 2026, 21:38 PM -
A NOVEL BIOMARKER FOR THE EARLY DETECTION OF DIABETIC KIDNEY DISEASE: A BUDGET IMPACT ANALYSIS
Mar 18, 2026, 21:38 PM -
EVIDENCE FOR MEANINGFUL PATIENT BENEFIT OF PEGCETACOPLAN IN C3G AND PRIMARY IC-MPGN FROM THE VALIANT TRIAL
Mar 18, 2026, 21:38 PM -
FINANCIAL HARDSHIP, MEDICATION MANAGEMENT BEHAVIORS, AND PERCEIVED QUALITY OF CARE AMONG MEDICARE BENEFICIARIES
Mar 18, 2026, 21:38 PM -
APPLICATION OF CAUSAL FOREST TO IDENTIFY IMPORTANT FEATURES TO EVALUATE HETEROGENEOUS TREATMENT EFFECTS OF DISEASE-MODIFYING THERAPIES IN MULTIPLE SCLEROSIS
Mar 18, 2026, 21:38 PM -
PHYSICIAN-LED CHART ABSTRACTION (PLCA) IN ONCOLOGY: ADVANCING FDA FIT-FOR-USE REAL-WORLD DATA FOR HEOR DECISION-MAKING
Mar 18, 2026, 21:38 PM -
ANTI-OSTEOPOROSIS DRUGS PRESCRIPTIONS AMONG OSTEOPOROSIS PATIENTS WITH T2DM IN CHINA
Mar 18, 2026, 21:38 PM -
VARIATION IN CASGEVY AND LYFGENIA COVERAGE CRITERIA ACROSS STATE MEDICAID PLANS
Mar 18, 2026, 21:38 PM -
SOCIODEMOGRAPHIC AND CLINICAL FACTORS ASSOCIATED WITH TIME TO TREATMENT INITIATION AND CARE PATHWAYS IN NON-METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA: A REAL-WORLD EVIDENCE STUDY
Mar 18, 2026, 21:38 PM -
PSYCHOSOCIAL AND SUPPORTIVE INTERVENTIONS FOR CAREGIVERS OF INDIVIDUALS WITH DEMENTIA: A SYSTEMATIC REVIEW
Mar 18, 2026, 21:38 PM
